Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous Stem Cell Transplantation With CD34-Selected Peripheral Blood Stem Cells (PBSC) in Patients With Treatment Resistant Systemic Sclerosis (SSc)

Trial Profile

Autologous Stem Cell Transplantation With CD34-Selected Peripheral Blood Stem Cells (PBSC) in Patients With Treatment Resistant Systemic Sclerosis (SSc)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary) ; Antithymocyte globulin (Primary) ; Cyclophosphamide (Primary) ; Filgrastim (Primary) ; Immune globulin (Primary) ; Mesna (Primary) ; Rituximab (Primary) ; Thiotepa (Primary)
  • Indications Systemic scleroderma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Sep 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2024.
    • 13 Dec 2022 Results(n=4, adolescent and young adult) assessing the effect of Autologous Stem Cell Transplantation (ASCT) for Refractory Juvenile-Onset Systemic Sclerosis presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 17 Dec 2021 Antithymocyte-globulin has been added to the study drug regimen. Inclusion criteria has been updated to change the age limits from 16 - 70 years to 8 years -60 years thus including child population and excluding elderly population.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top